Pharmafile Logo
Pharmafocus logo
Advanced Search

Movectro

Showing 8 posts of 8 posts found.

Merck KGaA

Merck scraps MS pill cladribine

June 23, 2011
Research and Development, Sales and Marketing Cladribine, Merck KGaA, Movectro, multiple sclerosis

Merck KGaA has pulled all pending applications for its multiple sclerosis pill Movectro and will withdraw it from the markets …

News
EMD Serono headquarters

FDA knocks back Merck KGaA’s oral MS drug

March 2, 2011
Sales and Marketing Cladribine, EMD Serono, FDA, MS, Merck KGaA, Movectro, multiple sclerosis, oral MS drugs

US authorities have turned down Merck KGaA’s new drug application for its oral relapsing-remitting multiple sclerosis treatment Movectro. The FDA …

News
Merck KGaA

Merck KGaA sales soar

February 21, 2011
Sales and Marketing 2010 pharma results, Cladribine, Merck KGaA, Merck Serono, Movectro

Merck KGaA’s sales jumped last year by nearly a fifth as recent acquisitions and strong growth on core products set …

News
Blog footer

Digital Pharma: Merck Serono sets up MS social network

February 18, 2011
Medical Communications Digital Pharma blog, MS, Merck Serono, Movectro, Rebif, multiple sclerosis, social networking

Merck Serono has set up an international social network for multiple sclerosis patients, saying today’s pharma companies should go beyond …

News
Merck Serono headquarters

Merck Serono halts Movectro European licence application

February 18, 2011
Medical Communications, Sales and Marketing Cladribine, MS, Merck KGaA, Merck Serono, Movectro, fingolimod, gilenya, multiple sclerosis

Merck Serono has withdrawn its European licence application for multiple sclerosis drug Movectro. Movectro (cladribine) is a new oral treatment …

News

Key drug launches for 2011

January 20, 2011
Sales and Marketing Benlysta, Cladribine, Movectro, Pradaxa, Xarelto, axitinib, boceprevir, crizotinib, telaprevir

This year is expected to see new treatments for hepatitis C, multiple sclerosis and lupus among those that could reach …

Feature

Merck will appeal EMA’s Movectro decision

October 12, 2010
Sales and Marketing CHMP, EMA, Merck KGaA, Merck Serono, Movectro

Merck KGaA is poised to appeal the EMA’s decision on its MS treatment Movectro after the regulator rejected the drug …

News

First oral MS treatment approved in Russia

July 12, 2010
Sales and Marketing Cladribine, MS, Merck Serono, Movectro

Regulators in Russia have approved Merck Serono’s cladribine, lining up the drug to be the first oral treatment for multiple …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024